ProCE Banner Activity

Our Experiences With the Expanded Role of BRCA Testing and Adjuvant PARP Inhibition in Early Breast Cancer

Clinical Thought

Banu Arun, MD; Allison Butts, PharmD, BCOP; and Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP, discuss their experiences and challenges with implementing recent data on BRCA testing and adjuvant PARP inhibition in early breast cancer.

Released: April 05, 2023



Banu Arun

Banu Arun, MD

Professor, Breast Medical Oncology
Co-Director, Clinical Cancer Genetics 
Executive Director, Cancer Genetics
MD Anderson Cancer Networks
University of Texas MD Anderson Cancer Center
Houston, Texas

Allison Butts

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
UK Healthcare
Lexington, Kentucky

Marissa Marti-Smith

Marissa Marti-Smith, APRN, AGNP-C, AOCNP

Nurse Practitioner
Breast Oncology
Texas Oncology Baylor Sammons Cancer Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from


Merck Sharp & Dohme, LLC



ProCE Banner


Banu Arun, MD: researcher: AstraZeneca.

Allison Butts, PharmD, BCOP: consultant/advisor/speaker: AstraZeneca, BeyondSpring.

Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP, has no relevant financial relationships to disclose.